Surgery May Help Some Pancreatic Cancer Patients With Limited Liver Spread

Pancreatic cancer is often aggressive, and when it spreads to the liver, treatment usually focuses on chemotherapy instead of surgery. But a new study from Japan suggests that in select patients, surgery may offer long-term survival.

The study followed 60 patients with pancreatic cancer that had also spread to the liver but only in a limited way, called oligometastasis. Researchers compared patients who had surgery immediately with those who first received chemotherapy and then surgery.

Patients who had chemotherapy before surgery lived much longer than those who had surgery right away (about 37 months vs. 20 months). In some cases, chemotherapy even made the cancer shrink completely before surgery.

The study also found three key factors linked to better survival after surgery:
– Low CA19-9 levels (a blood marker for pancreatic cancer)
– Low CEA levels (another tumor marker)
– Tumors that were resectable or borderline resectable in relation to the portal vein

Patients who met all three conditions had an impressive median survival of almost 9 years (106 months) after surgery, showing that long-term survival is possible under the right circumstances.

This research highlights the importance of careful patient selection. Surgery is not suitable for everyone with pancreatic cancer and liver metastasis, but for those meeting specific conditions and responding well to chemotherapy, it may be a powerful option.